Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue dips below year-ago levels

Q2 FY2026 cost of revenue of $271.72M fell 1.6% year over year, behind the +7.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +17.3% a year.

Context

  • Cost of revenue amounted to 80.5% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.6% toward the trailing-twelve-month pace of +7.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$271.72M+4.4% QoQ
Last fiscal yearDec 2025
$1.17B+18.6% YoY
LTMJun 2026
$1.15B+7.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year+18.6%——
3-year CAGR+17.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.17B USD
Year-over-year change
+18.6%
4-year CAGR
+16.6%

Cost of Revenue vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 cost of revenue of $1.15B is the 3rd highest of the 11 companies compared; the peer median is $146.57M.
  • Its year-over-year change of +7.6% is the 4th highest of 10, against a peer median of -0.3%.
  • Cost of revenue amounts to 78.4% of revenue for GRDN, versus a peer median of 45.9%.
GRDN Competitors Peer median
Cost of Revenue for GRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDPediatrix Medical Group, Inc.LTM Sep 2026$1.53B +7.1%-1.4%78.0%
QDELQuidelOrtho CorporationLTM Mar 2026$1.46B -0.3%+3.1%55.0%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$1.15B +7.6%+17.3%78.4%
NHCNational HealthCare CorporationLTM Sep 2026$1.08B +16.9%+10.3%68.0%
TWSTTwist Bioscience CorporationLTM Sep 2026$218.63M +17.8%+12.1%47.6%
TXG10x Genomics, Inc.LTM Sep 2026$173.93M -13.0%+18.2%28.1%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$119.22M +28.3%+43.4%37.0%
MESOMesoblast LimitedLTM Jun 2026$19.21M -63.8%-29.5%16.0%
NUVBNuvation Bio Inc.LTM Jun 2026$10.3M -1.0%—6.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M -79.7%+34.1%45.9%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$590K ———
Peer median (excluding GRDN) $146.57M-0.3%+11.2%45.9%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue792.07M908.91M1.05B1.23B1.45B
Cost of Revenue630.81M723.04M837.88M984.04M1.17B
Gross Profit161.27M185.87M208.31M244.37M282.04M
Gross Margin20.4%20.4%19.9%19.9%19.5%
Research & Development00000
Selling, General & Admin131.12M133.88M167.36M307.29M193.13M
Operating Expenses131.12M133.88M167.36M307.29M193.13M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
EBITDA46.49M68.15M58.81M(43.43M)96.42M
EBITDA Margin5.9%7.5%5.6%-3.5%6.7%
Operating Income30.15M51.99M40.95M(62.92M)88.91M
Operating Margin3.8%5.7%3.9%-5.1%6.1%
Interest Income00000
Interest Expense1.64M1.93M2.86M3.28M665K
Other Income / Expenses(1.82M)(2.33M)(3.23M)(3.56M)(15.49M)
Income Before Tax28.33M49.66M37.72M(66.48M)73.42M
Pre-Tax Margin3.6%5.5%3.6%-5.4%5.1%
Income Tax Expense0004.56M24.47M
Net Income16.31M35.42M23.9M(87.29M)49.22M
Net Margin2.1%3.9%2.3%-7.1%3.4%
EPS (Basic)0.270.580.39(1.77)0.79
EPS (Diluted)0.270.580.39(1.77)0.78
Weighted Avg Shares60.84M60.84M60.84M62.01M62.39M
Weighted Avg Shares (Diluted)60.84M60.84M60.84M62.01M63.3M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.